Theravance : Media

Wednesday, March 17, 2010
Theravance Announces Proposed Public Offering of Common Stock
Thursday, February 25, 2010
Theravance to Present at Investor Conferences in March 2010
Thursday, February 11, 2010
Theravance Reports Fourth Quarter and Full Year 2009 Financial Results
Wednesday, February 3, 2010
Theravance to Report Fourth Quarter and Full Year 2009 Financial Results on February 11, 2010
Thursday, January 28, 2010
Theravance Announces Receipt of Additional FDA Communication Regarding Telavancin NDA for the Treatment of Nosocomial Pneumonia
Thursday, January 7, 2010
Theravance to Present at the 28th Annual J.P. Morgan Healthcare Conference
Wednesday, December 2, 2009
Theravance to Present at the Deutsche Bank 2009 Biotech Boston Confab
Monday, November 30, 2009
Theravance Announces That EMEA Has Completed the Validation Phase for the Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections
Friday, November 27, 2009
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Thursday, November 5, 2009
Theravance and Astellas Announce the Commercial Launch of VIBATIV( TM ) (telavancin) in the United States
Tuesday, November 3, 2009
Theravance to Present at the 18th Annual Credit Suisse Health Care Conference
Wednesday, October 28, 2009
Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe
Tuesday, October 27, 2009
Theravance Reports Third Quarter 2009 Financial Results
Tuesday, October 27, 2009
GlaxoSmithKline and Theravance commence Phase III Horizon programme to develop a next-generation treatment for COPD
Thursday, October 22, 2009
Theravance Earns $20 Million Milestone Under Telavancin Collaboration Agreement
Monday, October 19, 2009
Theravance to Report Third Quarter 2009 Financial Results on October 27, 2009
Thursday, October 1, 2009
Astellas and Theravance Announce Approval of VIBATIV(TM) (telavancin) in Canada for the Treatment of Complicated Skin and Skin Structure Infections
Friday, September 11, 2009
Theravance and Astellas Announce FDA Approval of VIBATIV(TM) (telavancin) for the Treatment of Complicated Skin and Skin Structure Infections
Wednesday, September 2, 2009
Theravance to Present at Investor Conferences in September 2009
Thursday, July 23, 2009
Theravance Reports Second Quarter 2009 Financial Results
Thursday, July 9, 2009
Theravance to Report Second Quarter 2009 Financial Results on July 23, 2009
Tuesday, June 2, 2009
Theravance to Present at Investor Conferences in June 2009
Thursday, April 30, 2009
Theravance to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
Friday, April 24, 2009
FDA Accepts for Review Theravance's Complete Response Submission for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
Wednesday, April 22, 2009
Theravance Reports First Quarter 2009 Financial Results

www.VIBATIV.com